UCL begins first UK deep brain stimulation study for children with rare epilepsy
Lennox-Gastaut syndrome affects up to 5% of children living with paediatric epilepsy
Read More
Tag: Lennox-Gastaut Syndrome
FDA approves GW’s cannabinoid drug Epidiolex
GW Pharmaceuticals’ Epidiolex has become the first cannabinoid prescription medicine to be approved in the US, winning clearance to treat two rare forms of epilepsy.
Read More
NEJM publishes second successful Epidiolex trial in LGS
The New England Journal of Medicine has published the second of two late stage studies showing that GW Pharma’s cannabinoid Epidiolex cut seizures in patients with the rare childhood epilepsy Lennox-Gastaut Syndrome.
Read More
GW’s Epidiolex on track for LGS filing mid-year
GW Pharma’s Epidiolex has impressed again in a late-stage trial involving patients with the rare form of epilepsy Lennox-Gastaut Syndrome (LGS), significantly reducing the number of drop seizures experienced.
Read More
Orphan status for GW’s rare epilepsy drug
London, UK-based GW Pharmaceuticals’ cannabinoid Epidiolex has been awarded Orphan status by European regulators as a treatment for Lennox-Gastaut Syndrome (LGS), a rare and severe form of childhood-onset epilepsy.
Read More
GW Pharma’s Epidiolex hits targets in rare epilepsy trial
GW Pharmaceuticals’ cannabinoid Epidiolex continues to impress in late-stage clinical trials, with a Phase III study involving patients with Lennox-Gastaut syndrome – a rare and severe form of childhood-onset epilepsy – the latest to hit its targets.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
